Previous Article | Next Article 
Journal of Bacteriology, August 2001, p. 4526-4535, Vol. 183, No. 15
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.15.4526-4535.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of the Domains of UreR, an AraC-Like
Transcriptional Regulator of the Urease Gene Cluster in
Proteus mirabilis
Carrie A.
Poore,
Christopher
Coker,
Jonathan D.
Dattelbaum, and
Harry L. T.
Mobley*
Department of Microbiology and Immunology,
University of Maryland, Baltimore, School of Medicine, Baltimore,
Maryland 21201
Received 20 February 2001/Accepted 18 May 2001
 |
ABSTRACT |
Proteus mirabilis urease catalyzes the hydrolysis of
urea to CO2 and NH3, resulting in urinary
stone formation in individuals with complicated urinary tract
infections. UreR, a member of the AraC family, activates transcription
of the genes encoding urease enzyme subunits and accessory proteins,
ureDABCEFG, as well as its own transcription in
the presence of urea. Based on sequence homology with AraC, we
hypothesized that UreR contains both a dimerization domain and a
DNA-binding domain. A translational fusion of the leucine zipper
dimerization domain (amino acids 302 to 350) of C/EBP and the
C-terminal half of UreR (amino acids 164 to 293) activated
transcription from the ureD promoter
(pureD) and bound to a 60-bp fragment
containing pureD, as analyzed by gel shift.
These results were consistent with the DNA-binding specificity residing
in the C-terminal half of UreR and dimerization being required for
activity. To localize the dimerization domain of UreR, a translational
fusion of the DNA-binding domain of the LexA repressor (amino acids 1 to 87) and the N-terminal half of UreR (amino acids 1 to 182) was
constructed and found to repress transcription from
psulA-lacZ (sulA is
repressed by LexA) and bind to the sulA operator site, as
analyzed by gel shift. Since LexA binds this site only as a dimer, the
UreR1-182-LexA1-87 fusion also must
dimerize to bind psulA. Indeed, purified UreR-Myc-His eluted from a gel filtration column as a
dimer. Therefore, we conclude that the dimerization domain of UreR is
located within the N-terminal half of UreR. UreR contains three
leucines that mimic the leucines that contribute to dimerization of
AraC. Mutagenesis of Leu147, Leu148, or L158 alone did not
significantly affect UreR function. In contrast, mutagenesis of both
Leu147 and Leu148 or all three Leu residues resulted in a 85 or 94%
decrease, respectively, in UreR function in the presence of urea
(P < 0.001). On the contrary, His102 and His175
mutations of UreR resulted in constitutive induction in the absence of
urea. We conclude that a dimerization domain resides in the N-terminal
half of the polypeptide, that Leu residues may contribute to this
function, and that sequences within the C-terminal half of UreR are
responsible for DNA binding to the urease promoter regions. Selected
His residues also contribute significantly to UreR function.
 |
INTRODUCTION |
Proteus mirabilis infects
the urinary tract of humans and is most commonly responsible for
causing disease in individuals with structural abnormalities of the
urinary tract or in patients who undergo long-term catheterization
(16). Cystitis, acute pyelonephritis, and urinary stone
formation are all possible consequences of P. mirabilis
infection (17).
P. mirabilis produces a urea-inducible urease, a
high-molecular-weight, multimeric, cytoplasmic nickel metalloenzyme.
Urease catalyzes the hydrolysis of urea to ammonia and carbon dioxide (18). During the course of infection, the production of
ammonia by urea hydrolysis raises the pH in the local environment,
subsequently precipitating polyvalent ions that are normally soluble in
urine. The result is the formation of urinary stones. The elevated pH also creates an environment that is more favorable for growth of this
species (4). Increased ammonia production can also lead to
acute inflammation with possible tissue necrosis (18).
The P. mirabilis urease gene cluster is found in single copy
on the chromosome and consists of eight contiguous genes,
ureRDABCEFG (12, 19, 24). The
ureA (UreA, 11 kDa), ureB (UreB, 12 kDa), and
ureC (UreC, 61 kDa) genes encode the structural polypeptides required for the assembly of a catalytically inactive urease apoenzyme (18). The accessory genes, ureD (UreD, 31 kDa),
ureE (UreE, 18 kDa), ureF (UreF, 23 kDa), and
ureG (UreG, 22 kDa), encode proteins required for insertion
of nickel ions into the metalloenzyme resulting in catalytically active
urease (18). The urease gene cluster is regulated by the
gene product of ureR (UreR, 33 kDa).
P. mirabilis UreR and the plasmid-encoded UreR found in
Escherichia coli are positive transcriptional activators of
the urease genes. The two proteins share 70% amino acid identity
(6) and are functionally interchangeable in the activation
of transcription from the ureR
(pureR) and ureD
(pureD) promoters in both the P. mirabilis and plasmid-encoded urease gene clusters (6). The UreR binding sites of both promoters have the
consensus sequence
T(A/G)(T/C)(A/T)(T/G)(C/T)T(A/T)(T/A)ATTG
(25). Both UreR proteins have been shown to activate
transcription from pureD in the presence of urea
(11, 6). In addition, UreR regulates its own
transcription in the presence of urea from pureR in the direction opposite the rest of the gene cluster
(6). In the absence of urea induction, H-NS represses
ureR expression (3). Because UreR activates
transcription in a urea-inducible manner, it is hypothesized that UreR
binds urea; however, this has not been directly demonstrated.
UreR is a member of the AraC family of transcriptional regulators and
contains a putative helix-turn-helix in addition to an AraC signature
sequence (5, 19). The AraC signature sequence, found
within all AraC family members, is a second helix-turn-helix that is
hypothesized to also bind DNA (7). Moreover, UreR also contains three conserved leucine residues (Leu147, Leu148, and Leu158)
in the same relative location with the same spatial distance relative
to each other as in AraC (Leu150, Leu151, and Leu161). These leucine
residues are critical for AraC dimerization (23), and we
therefore also hypothesize that UreR dimerizes via this mechanism. In
the presence of arabinose, AraC uses these three critical leucines for
dimerization via an antiparallel coiled-coil in a
"knobs-into-holes" manner, as elucidated by X-ray crystallographic studies (23). This coiled-coil is also the primary
dimerization face in the absence of arabinose, shown by both size
exclusion chromatography and sedimentation velocity analytical
ultracentrifugation of an AraC mutant with mutations in Leu150, Leu151,
Asn154, and Leu161 (15). A secondary dimerization face in
the
barrel of AraC is evident; however, it does not appear to
represent the primary means of dimer interaction (15).
AraC contains two separate and independent domains, each with a
distinct function, namely, dimerization and DNA binding; UreR is
predicted to have similar domains with similar functions. Previously, chimeric proteins containing the two domains of AraC to characterize each of the domain's functions were synthesized (2). The
predicted AraC DNA-binding domain was fused to C/EBP, a known
eukaryotic transcriptional activator that dimerizes via a leucine
zipper. The C/EBP-AraC fusion was found to bind to
pBAD and activate transcription
(2). The hypothesized AraC dimerization domain was fused
to the LexA DNA-binding domain. This fusion was predicted to mimic full-length LexA and demonstrated the need for
dimerization in order to repress transcription of genes normally turned
off by LexA. A chromosomal transcriptional fusion of
psulA to lacZ was repressed in the
presence of the AraC-LexA fusion protein. This strategy was used to
identify both domains of AraC (2).
In this study, we constructed fusion proteins to identify putative
domains of UreR and assign dimerization and DNA-binding functions to
each of the domains as well as identifying key amino acid residues
involved in dimerization and urea induction.
 |
MATERIALS AND METHODS |
Chemicals and enzymes.
All enzymes were purchased from Life
Technologies (Rockville, Md.) or New England Biolabs (Beverly, Mass.).
All chemicals were purchased from Sigma-Aldrich (St. Louis, Mo.) unless
otherwise noted. The DIG (digoxigenin) gel shift kit was obtained from
Amersham Pharmacia Biotech (Piscataway, N.J.).
Bacterial strains and growth conditions.
Bacterial strains
used in this study are listed in Table 1.
Bacteria were grown either in Luria-Bertani (LB) broth at 37°C with
aeration in a shaking incubator (200 rpm) or on LB plates containing
1.5% agar at 37°C. Plates and media were supplemented with the
antibiotic chloramphenicol (10 µg/ml), tetracycline (7.5 µg/ml),
ampicillin (100 µg/ml), or kanamycin (50 µg/ml).
PCR amplification of DNA used to make fusion proteins.
PCR
primers are listed in Table 2. The
amplification protocol for PCRs was as follows: denaturation, 94°C, 3 min; annealing, 50 to 55°C, 45 s; elongation, 72°C, 1 min; for
30 cycles.
Cloning of PCR products.
PCR products were ligated into
pCR-BluntII-TOPO (Invitrogen, Carlsbad, Calif.). Inserts were excised
using the appropriate restriction enzymes (either
NcoI-BamHI, BamHI-XhoI,
NcoI-XhoI, or
NcoI-HindIII) and separated by agarose
gel electrophoresis. PCR amplification products for the inserts
encoding C/EBP302-350-Myc-His and
LexA1-87-Myc-His were digested with restriction enzymes; Table 2 lists inserts and restriction enzymes used. All constructs use
an NcoI site to ligate into the vector at the gene sequence encoding the start codon. A BamHI site is at the junction of
the gene sequences encoding the domains in both
C/EBP302-350-UreR164-293 and
UreR1-182-LexA1-87. All constructs
except the gene sequences encoding UreR-Myc-His,
UreR164-293-Myc-His, C/EBP302-350-Myc-His, LexA1-87-Myc-His,
L147A-L148-Myc-His, and L147A-L148A-L158A-Myc-His, which use a 3'
HindIII site, contain a XhoI site at the 3'
end for cloning into the expression vector. Inserts were purified using
a Qiaquick gel extraction kit (Qiagen) and ligated into either
pBAD/MHA or pSE380 (Invitrogen). Plasmids were introduced into the
corresponding laboratory strain by CaCl2 transformation
(21). The LexA1-87-Myc-His gene sequence was
ligated into pBAD/MHA to take advantage of the Myc-His epitopes. After transformation, the pBAD vector containing the gene sequence encoding LexA1-87-Myc-His was purified using a Qiagen
miniprep kit. The plasmid was then used in a PCR with primers to
amplify the gene sequence for LexA1-87-Myc-His. The PCR
product was then cut with NcoI and XhoI and
ligated into the NcoI and XhoI sites in pSE380.
Construction of pureD-lacZ
reporter plasmid.
A low-copy-number ureD-lacZ fusion
reporter plasmid compatible with pBAD-Myc-His was constructed. Primers
MOB906 and MOB915 were used to PCR amplify an approximately 4.3 kb DNA
fragment from plasmid p
R10 ureD-lacZ (11)
under the following conditions: 95°C denaturation, 54°C annealing,
and 72°C elongation for 30 cycles, using Vent DNA polymerase in the
presence of 1 mM MgSO4. The PCR product was gel purified
and ligated to PCR-Blunt (Invitrogen), forming pCC026. pCC026 was
digested with EcoRI, and the 4.3-kb DNA fragment encoding
ureD-lacZ was ligated to an EcoRI-digested derivative of pACYC184 that had previously been cut with
PvuII and religated (thus, it does not encode a functional
chloramphenicol acetyltransferase). The resulting recombinant plasmid,
pCC042, carries a tetracycline resistance marker and encodes a
ureD-lacZ transcriptional fusion that is activated in the
presence of UreR and urea.
Sequencing.
Both strands of plasmid constructs were
sequenced across each junction and throughout the insert. Sequencing
was done by the Biopolymer Laboratory at the University of Maryland, Baltimore.
-Galactosidase expression assays.
Fresh medium was
inoculated with a single colony from LB-agar plates containing the
appropriate antibiotics and cultured at 37°C overnight. Overnight
cultures were used to inoculate fresh medium. Cultures were monitored
until they reached an optical density at 600 nm (OD600) of
~0.4 to 0.6, at which time inducer (isopropyl-
-D-thiogalactopyranoside [IPTG], arabinose,
or urea) was added, and cultures were incubated for an additional hour. Cultures were placed on ice, and the OD600 was measured.
Chloroform (100 µl) and 0.1% sodium dodecyl sulfate (SDS; 50 µl)
were added, and cultures were vortexed. The suspension of permeabilized
cells (10 µl) was added to 990 µl of Z buffer and 200 µl of
o-nitrophenyl-
-D-galactopyranoside (4 mg/ml in H2O). Timed reactions were stopped with 500 µl
of 1 M Na2CO3. OD420 and
OD550 measurements were recorded, and Miller units were
calculated (20). All constructs were assayed in three or
more independent experiments.
Western blot analysis.
Overnight cultures were used to
inoculate 4 ml of fresh LB medium containing the appropriate
antibiotics and allowed to grow to mid-exponential phase. Cultures were
induced with the appropriate inducer and incubated for the indicated
time. Cultures were placed on ice. OD600 was determined,
and all cultures were adjusted to the same reading. Bacteria were
harvested from 1 ml of culture by centrifugation and resuspended in
equivalent amounts of Laemmli sample buffer. Samples were boiled for 5 min and placed on ice. The sample volume listed for each experiment was
loaded onto a 3.75% stacking and either a 12.5 or 15%
SDS-polyacrylamide gel by the method of Laemmli (13). SDS
running buffer was used for electrophoresis. Gels were transferred onto
Immobilon P membranes in a transfer chamber containing transfer buffer.
Transfer occurred overnight at ~12 V at 4°C. Membranes were blocked
in 5% dry milk in 0.1% TTBS (20 mM Tris-HCl [pH 7.5], 150 mM NaCl,
0.1% Tween 20) for 1 h. Primary antibodies were added to 0.1%
TTBS (anti-LexA, anti-Myc and anti-His, diluted 1:5,000), and membranes
were exposed to antibodies for 2 h at room temperature. Membranes were
washed in 0.1% TTBS three times for 15 min each. Secondary antibodies (anti-mouse immunoglobulin G coupled to alkaline phosphatase detected anti-Myc and anti-His antibodies; anti-rabbit immunoglobulin G coupled
to alkaline phosphatase detected anti-LexA antibodies) were placed in
0.1% TTBS (dilution 1:2,000), and membranes were incubated in the
secondary antibodies for 1 h. Membranes were washed three times
for 15 min each in 0.1% TTBS and developed with nitroblue
tetrazolium-5-bromo-4-chloro-3-indolylphosphate dissolved in
H2O (according to the Western blot protocol as described in
reference 1).
Gel shift analysis.
Gel shift experiments used either a
60-bp (DNA-binding domain study) or a 64-bp (dimerization study)
double-stranded oligonucleotide that was synthesized from smaller
overlapping oligonucleotide fragments that were allowed to anneal and
extend using Vent polymerase. One microliter of each reaction was run
on a gel for quantification purposes. Both double-stranded
oligonucleotides (3.85 pmol of each) were labeled by the DIG gel shift
(Amersham Pharmacia) protocol. Each double-stranded oligonucleotide was
diluted to 30 fmol for the binding study.
Overnight cultures were used to inoculate fresh LB medium containing
appropriate antibiotics. These cultures were grown to mid-exponential
phase. The appropriate inducer molecule was added and incubated
further. The cultures were placed on ice, and OD600 measurements were taken. OD600 for all cultures was
adjusted to the same reading by using LB medium. Equivalent volumes of
each culture were centrifuged, and the pellet was resuspended in 1 ml
of TEN buffer (10 mM Tris, 1 mM EDTA, 0.1 M NaCl [pH 8.0]). Bacterial
suspensions were disrupted by passage through a French press (18,000 lb/in2). Lysates were centrifuged (12,000 × g, 10 min, 4°C). Supernatants were collected and used as the
extract for the binding assay. The binding assay was done as instructed
by the DIG gel shift kit manufacturer (Amersham Pharmacia), using
binding buffer, 1 µg of poly(dI-dC), 1 µg of
poly-L-lysine, specific extract volume, and 2 µl of the
labeled DNA. Binding reactions for pBAD, UreR, C/EBP302-350-UreR164-293, and
UreR-Myc-His also included 100 mM urea (final concentration). The
binding reactions were run on a preelectrophoresed 6% native
polyacrylamide gel in TAE buffer (0.04 M Tris acetate, 0.001 M EDTA) at
90 V for 1.5 h. The gel was placed on a Hybond N+ membrane and
transferred for 30 min at 400 mA in 1× TAE buffer. The membrane was
developed according to the instructions of the DIG gel shift kit
manufacturer (Amersham Pharmacia).
Purification of UreR derivatives.
E. coli Top10
transformed with pCP016 or pCP088 was grown in Luria broth at 37°C.
Expression of UreR-Myc-His6 was induced with 0.2%
arabinose when an OD600 of ~0.6 was reached. Following 3 h of induction, cells were collected by centrifugation and lysed by two passages through a French pressure cell (18,000 lb/in2). Single-step purification of
UreR-Myc-His6 was performed by nickel-chelating
nitrilotriacetic acid affinity chromatography. A single polypeptide of
approximately 33 kDa was eluted from the column with 250 mM imidazole
as seen on a Coomassie blue-stained 12% SDS-polyacrylamide gel
(data not shown). In a similar experiment, purified protein was
electrophoresed, transferred to a nitrocellulose membrane, and reacted
with rabbit antiserum specific for the Myc epitope. Western blot
anlysis showed that arabinose-induced E. coli Top10
transformed with either pCP016 or pCP088 produced a single species of
33 kDa, consistent with the predicted size for UreR-Myc-His6 (see Fig. 3). The band was absent from
the vector control under identical conditions.
Gel filtration chromatography.
Gel filtration chromatography
was performed at room temperature on a Sephadex G-75 column (1 by 35 cm) equilibrated with running buffer (50 mM phosphate [pH 7.5], 150 mM NaCl) at a flow rate of 0.5 ml/min. Molecular weight standards
bovine serum albumin (68 kDa) and carbonic anhydrase (34.5 kDa) were
used to calibrate the column. Purified wild-type and mutant
UreR-Myc-His6 proteins (100 µl of 0.1 mg/ml) were
injected onto the column, and 0.5-ml fractions were collected. The
protein elution profile was monitored by absorbance at 280 nm. An
aliquot (100 µl) of each fraction was transferred to an Immobilon P
membrane, and immunoblot analysis performed with anti-Myc antibodies.
 |
RESULTS |
Localization of the UreR DNA-binding domain.
To localize the
UreR DNA-binding domain, a protein chimera was constructed by fusing
the gene sequence encoding the C-terminal half of UreR to the gene
sequence encoding the leucine zipper dimerization domain of C/EBP (Fig.
1; primers are listed in Table 2). All
translational fusion constructs were cloned into the E. coli
arabinose-inducible expression vector pBAD/Myc-His A (Invitrogen) (Table 1). A pureD-lacZ plasmid
reporter was constructed in pACYC184 to assay specific induction of the
urease gene cluster, using
-galactosidase activity as the readout.
Both reporter plasmid and pBAD constructs with and without insert were
transformed into E. coli Top10.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic of fusion constructs. The domain structure of
each of the chimeric proteins is shown; the amino acid residue number
is labeled at each boundary. A BamHI restriction site
(coding for a Gly-Ser amino acid linker (GS)) was inserted between gene
sequences encoding each domain. Key leucine residues and
helix-turn-helix motifs (H-T-H) are indicated. Sig., signature.
|
|
The C/EBP302-350-UreR164-293 fusion
chimera was tested for its ability to bind to
pureD and activate transcription. The
C/EBP302-350-UreR164-293 fusion activated
transcription from this promoter in both the absence (264% of
uninduced wild-type UreR level) and presence (42% of urea-induced
wild-type UreR level) of urea (Fig. 2).
The level of activation of pureD, mediated by
C/EBP302-350-UreR164-293 and measured by
the
-galactosidase assay, was not significantly different in the
presence and absence of urea. This result is consistent with the
urea-binding domain not residing in the C-terminal half of UreR or urea
binding not affecting DNA binding in the chimera.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
-Galactosidase assays using
pureD-lacZ reporter construct. -Galactosidase
activity was measured in E. coli Top10 transformed with the
pureD-lacZ reporter construct and the chimeric
fusion constructs. Cultures (4 ml) were grown in LB medium to
mid-exponential phase and induced with 0.02% arabinose with or without
100 mM urea for 1 h. -Galactosidase activity is expressed in
Miller units (18). All constructs were assayed in
duplicate in at least three different experiments.
|
|
A UreR-Myc-His fusion was constructed so that UreR could be readily
detected on Western blots and in gel mobility shift assays. The
UreR-Myc-His fusion induced
-galactosidase expression using the
pureD-lacZ reporter construct and elicited
levels of expression that were not significantly different from
wild-type UreR level (104 and 73% of wild-type UreR activation in the
absence and presence of urea, respectively) (Fig. 2). Since we observed similar
-galactosidase expression from
pureD-lacZ for both UreR and UreR-Myc-His, we
considered these two proteins to be interchangeable in their ability to
regulate transcription. This translational fusion contains a c-Myc
epitope and His6 tail that are recognized by anti-Myc
(Invitrogen) and anti-His5 (Qiagen) monoclonal antibodies,
respectively. Expression of the UreR-Myc-His protein product was
verified by Western blotting. The translational fusion protein was
detected as a band corresponding to the expected molecular size of
~36 kDa with both anti-Myc (Fig. 3F)
and anti-His (Fig. 3A) antibodies.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 3.
Western blot analysis of fusion constructs. E. coli Top10 (A, B, C, and F) or E. coli JL1436 (D and
E), transformed with vector or clones expressing UreR or chimeric
proteins, was cultured in LB medium to mid-exponential phase and
induced with 2% arabinose for 4 h (unless otherwise noted). Samples
(10 µl) of each suspension were boiled for 5 min in gel sample buffer
and electrophoresed on an SDS-polyacrylamide gel. Membranes
were incubated with antiserum or monoclonal antibodies and
developed with secondary antibodies conjugated to alkaline
phosphotase (Sigma). (A) pBAD, UreR, UreR-Myc-His; 12.5%
SDS-polyacrylamide gel. Membranes were reacted with mouse
anti-His antibody (diluted 1:1,000) (Invitrogen). (B) pBAD,
UreR, UreR164-293, or
UreR164-293-Myc-His; 15% SDS-polyacrylamide gel.
Membranes were reacted with mouse anti-His antibody
(diluted 1:1,000) (Invitrogen). (C) pBAD, UreR,
C/EBP302-350, C/EBP302-350-Myc-His; 15%
SDS-polyacrylamide gel. Membranes were reacted with mouse anti-His
antibody (diluted 1:1,000) (Invitrogen). (D) LexA,
LexA1-87, LexA1-87-Myc-His; induced
with 2 mM IPTG. Samples (2 µl) of each were
electrophoresed on a 15% SDS-polyacrylamide gel. Membranes were
hybridized with rabbit polyclonal anti-LexA antibody (diluted
1:5,000) (Invitrogen). (E) LexA, LexA1-87,
UreR1-182-LexA1-87; induced
with 2 mM IPTG. Samples (1.25 µl) of each, including strain only,
were electrophoresed on a 12.5% SDS-polyacrylamide gel. Membranes were
reacted with rabbit polyclonal anti-LexA antibody (diluted 1:5,000)
(Invitrogen). (F) pBAD, UreR, UreR-Myc-His, UreR L147A-L148A, UreR
L147A-L148A-Myc-His, UreR L147A-L148A-L158A, and UreR
L147A-L148A-L158A-Myc-His; induced with 2% arabinose for 4 h.
Samples (10 µl) of each were electrophoresed on a 12.5%
SDS-polyacrylamide gel. Membranes were hybridized with mouse anti-Myc
antibody (diluted 1:5,000) (Invitrogen).
|
|
Neither the putative UreR DNA-binding domain alone
(amino acids 164 to 293) nor C/EBP302-350 alone
activated transcription from pureD in the
presence or absence of urea; values were below levels detected for the
vector plasmid DNA alone (Fig. 2). The stability of
UreR164-293 and C/EBP302-350 was examined
by translationally fusing Myc-His to the C-terminal end of both
truncated proteins. Both the UreR164-293 and the
C/EBP302-350 proteins showed negligible
-galactosidase activities that were not significantly different from their Myc-His fusion counterparts. Western blot analysis using monoclonal
anti-His5 (Qiagen) revealed that both the
UreR164-293-Myc-His (18 kDa) and the
C/EBP302-350-Myc-His (9 kDa) are produced (Fig. 3B and C).
DNA binding by UreR constructs assessed by gel shift.
Gel
shift experiments were performed to verify that
C/EBP302-350-UreR164-293 used in the
-galactosidase assays could bind to pureD. A
60-bp double-stranded oligonucleotide that contained the DNA sequence
for pureD (
66 to
6 upstream of the
transcriptional start of ureD) was synthesized and labeled
with DIG-11-ddUTP by terminal transferase.
Binding assays were performed with the labeled double-stranded
oligonucleotide, whole-cell extracts containing each of the overexpressed protein products, and 100 mM urea. A cell extract containing full-length UreR retarded the migration of the
double-stranded DNA (dsDNA) fragment, indicating that UreR protein
bound to DNA (Fig. 4). The fusion
protein, C/EBP302-350-UreR164-293, also
bound the labeled DNA, reflected by a somewhat less intense shifted
band. The UreR-Myc-His fusion protein bound and retarded the labeled
DNA as well as full-length UreR (data not shown). The pBAD vector
control lane showed a faint band at the highest concentration of
lysate; however, there are no other bands evident in the pBAD lanes
containing lower concentrations of protein. The limited nonspecific
binding seen in the vector control lane can likely be explained by the
use of whole-cell extracts incubated with the target DNA
(14). These results demonstrate that full-length UreR,
C/EBP302-350-UreR164-293, and
UreR-Myc-His bind to the pureD DNA
double-stranded oligonucleotide and are likely responsible for the
activation from pureD.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 4.
Gel mobility shift assay for interaction of UreR with
the P. mirabilis pureD. A 60-bp
double-stranded oligonucleotide was synthesized based on the sequence
of pureD. Whole-cell extracts of E. coli Top10 transformed with either pBAD or vector expressing
C/EBP302-350-UreR164-293 were
obtained by inducing a 4-ml culture in mid-exponential phase with 2%
arabinose for 4 h. Whole-cell extracts of E. coli Top10
expressing UreR and UreR-Myc-His were obtained by inducing a 4-ml
culture in mid-exponential phase with 2% arabinose and 100 mM urea for
4 h. Bacterial suspensions were adjusted to the same OD, and 3 ml
of each culture was harvested by centrifugation (10,000 × g, 5 min, 4°C). Bacteria were resuspended in 1 ml of TEN buffer
and lysed in a French press (18,000 1b/in2). Binding
reactions with the 60-bp pureD dsDNA
fragment were carried out in the presence of 100 mM urea with various
amounts of the extracts.
|
|
Localization of the UreR dimerization domain.
Protein chimeras
were constructed to localize the UreR dimerization domain. The gene
sequence encoding the N-terminal half (amino acids 1 to 182) of UreR
was fused to the gene sequence encoding the LexA DNA-binding domain
(amino acids 1 to 87), forming the
UreR1-182-LexA1-87 fusion protein (Fig.
1; primers are listed in Table 2). All fusion constructs used in these
experiments were cloned into pSE380 (Invitrogen) (Table 1) under the
control of an IPTG-inducible promoter. The reporter strain, JL1436
(Table 1), originally described by Bustos and Schleif (2),
consisted of a chromosomal transcriptional fusion of
psulA with lacZ placed downstream;
the sulA gene is repressed by dimerized LexA
(2).
The fusion proteins were assayed for the ability to repress
transcription of lacZ by binding to
psulA. As expected, both untransformed E. coli JL1436 and JL1436 transformed with full-length
ureR showed no repression of
-galactosidase expression (Fig. 5). The
UreR1-182-LexA1-87 fusion repressed transcription from psulA by factors of 70 and 56 in the absence and presence of urea, respectively, comparable to the results for full-length LexA (the repression factor is defined as the
Miller units of the strain only divided by the Miller units of the
strain carrying the expression vector). LexA has repression factors of
92 and 127 in the absence and presence of urea, respectively. The
LexA DNA-binding domain alone (LexA1-87) did not
repress, indicated by repression factors of only 8 in the absence of
urea and 4 in the presence of urea. As expected, the repression factors seen for both UreR1-182-LexA1-87 and
full-length LexA are not significantly different in the absence of
urea, showing that they are similar in the ability to repress
transcription from psulA. However, both
LexA and UreR1-182-LexA1-87 had
repression factors that were significantly different (P
0.001) from those of the LexA1-87 control in the
presence and absence of urea, suggesting that the LexA1-87
lacks a dimerization domain that was provided by
UreR1-182 to repress transcription.
UreR1-182-LexA1-87 did not repress
transcription in a urea-inducible manner.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
-Galactosidase reporter activity of the
psulA-lacZ chromosomal fusion reporter construct
in strain JL1436. E. coli JL1436 (carries a single copy of a
psulA-lacZ chromosomal fusion) transformed with
the chimeric fusion constructs was cultured in LB medium (4 ml) to
mid-exponential phase and induced with 2 mM IPTG with or without 100 mM
urea for 1 h. -Galactosidase levels measured in Miller units
(18) as an index of expression from
psulA-lacZ. The Repression factor was calculated
by dividing the Miller units for strain only (JL1436) by Miller units
for each construct in JL1436. All constructs were assayed in duplicate
for at least three independent experiments.
|
|
We noted that LexA1-87 was not stable on Western blots.
Thus, to examine whether lack of repression at the sulA
reporter was due to the lack of stability, we constructed another
control. LexA1-87 protein was translationally fused to
Myc-His at its C-terminal end. LexA1-87-Myc-His protein
also did not repress transcription from psulA,
as evidenced by
-galactosidase assays. LexA1-87, either
tagged or not with the Myc-His epitope, showed negligible
repression and values were not significantly different.
Expression of both full-length LexA and the
UreR1-182-LexA1-87 used in the
-galactosidase assay was also verified by Western blotting using an
anti-LexA polyclonal antibody (Invitrogen) (Fig. 3E). Strong signals
were observed in lanes containing LexA and
UreR1-182-LexA1-87. Western blot analysis
using anti-LexA showed a 13-kDa band corresponding to
LexA1-87-Myc-His (Fig. 3D). Therefore, the repression of
-galactosidase expression observed in the
UreR1-182-LexA1-87
-galactosidase assay was likely due to the expression of the fusion protein.
Binding of the UreR-LexA fusions to target DNA assayed by gel
shift.
Gel shift experiments were performed to show that the
fusion proteins as well as the LexA control bound to
psulA, providing an explanation for the
inhibition of transcription initiation from
psulA-lacZ. A 64-bp double-stranded
oligonucleotide comprising the LexA binding site upstream of
sulA (+26 to
38 relative to the transcriptional start of
sulA) was synthesized and labeled with DIG-11-ddUTP by
terminal transferase.
Lanes containing LexA revealed a strong signal representing a shifted
band (Fig. 6). The
UreR1-182-LexA1-87 lanes contained a
retarded band that was not as strong in intensity. Cell extracts from
JL1436 carrying no plasmid (Fig. 6) or JL1436 transformed with the
LexA1-87-Myc-His construct alone (data not shown) were
unable to retard the mobility of the dsDNA fragment.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 6.
Gel mobility shift assay for chimeric protein and the
LexA DNA-binding site upstream of psulA. A 64-bp
double-stranded oligonucleotide was synthesized based on the nucleotide
sequence of psulA. Whole-cell extracts were
obtained by inducing a 100-ml culture, in mid-exponential phase,
with 2 mM IPTG for 3 h. Culture (50 ml) was centrifuged, and
bacteria were resuspended in 1 ml of TEN buffer and lysed in a French
press (18,000 lb/in2). All lanes contained the labeled
64-bp dsDNA fragment. The lane containing no extract contained labeled
DNA only. JL1436, LexA, and
UreR1-182-LexA1-87 whole-cell extracts
were added at volumes of 10, 5, and 1 µl.
|
|
PCR site-directed mutagenesis of leucines in the putative UreR
dimerization domain.
AraC uses three critical leucines (Leu150,
Leu151, and Leu161) for dimerization via an antiparallel coiled-coil in
the absence and presence of arabinose (15). Due to the
conservation of these three leucines in both overall location and
spatial orientation within UreR, we hypothesized that these leucine
residues are important for dimerization of UreR. To directly test
biologically whether these Leu residues are required for dimerization
of UreR monomers, PCR site-directed mutagenesis (9) was
used to create leucine to alanine mutants of UreR in Leu147 (L147A)
alone, Leu148 (L148A) alone, Leu158 (L158A) alone, Leu147 and Leu148
(L147A-L148A), and Leu147, Leu148, and Leu158 (L147A-L148A-L158A).
-Galactosidase expression from the
pureD-lacZ reporter plasmid was
measured for each of the UreR leucine mutants in the presence and
absence of urea (Fig. 7). In the presence
of urea, the L147A, L148A, and L158A single mutants had levels of
expression that were 71, 89, and 137%, respectively, of the wild-type
UreR level. Thus, dimerization, required for activity, was not
dramatically altered. The L147A-L148A double mutant, however, had an
expression level that was only 15% of the wild-type UreR level in the
presence of urea, a significant drop in activity (P < 0.001). The expression level observed for the L147A-L148A-L158A
triple mutant, 6% of the wild-type UreR level (P < 0.001) in the presence of urea, tended to be even lower than that
of the double mutant (P = 0.052).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 7.
-Galactosidase assays using the
pureD-lacZ reporter construct to measure
activation by the UreR leucine mutants. E. coli
transformed with the Leu mutant constructs was cultured to mid-log
phase in LB medium (4 ml) and induced with 0.02% arabinose with
or without 100 mM urea for 1 h. -Galactosidase
activity represented expression from pureD-lacZ
and is expressed in Miller units. All constructs were assayed in
duplicate for at least three independent experiments.
|
|
To verify that both the double and triple mutant proteins were
expressed and stable, L147A-L148A and L147A-L148A-L158A were translationally fused to Myc-His. The L147A-L148-Myc-His protein activated from pureD to the same degree (15 and
8% of the wild-type UreR level in the absence and presence of urea, respectively) as seen for L147A-L148A protein in the
-galactosidase assay. The L147A-L148A-L158A-Myc-His protein activated from
pureD to the same degree (11 and 4% of the
wild-type UreR level in the absence and presence of urea, respectively)
as seen for L147A-L148A-L158A protein in the
-galactosidase assays.
Western blot analysis using monoclonal anti-Myc antibodies (Invitrogen)
confirmed the stable expression of two 36-kDa bands corresponding to
L147A-L148A-Myc-His and L147A-L148A-L158A-Myc-His (Fig. 3F).
Dimer formation in UreR derivatives.
To determine whether
the low activity of the triple Leu mutant of UreR-Myc-His was due a
loss of dimerization, we compared the elution profile of this protein
to that of UreR-Myc-His on a Sephadex G-75 gel filtration column. The
two proteins, purified from induced cell lysates on a
Ni-nitrilotriacetic acid column, were applied to the column. Both
UreR-Myc-His and the L147A-L148A-L158A-Myc-His derivative of
UreR eluted at fractions corresponding to the dimerized protein (Fig.
8). Thus, loss of activity in the
site-directed mutant was not due to the inability to dimerize.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 8.
Gel filtration chromatography of UreR-Myc-His and its
triple Leu mutant. Purified UreR-Myc-His and
UreR-L147A-L148A-L158A-Myc-His (3 X Leu mutant) (approximately 10 µg
of protein) were applied to a Sephadex G-75 column. Protein elution was
monitored at 280 nm. Fractions (0.5 ml) were collected, and aliquots of
the 3 X Leu mutant (0.15 ml) were assayed by immunoblotting using
anti-Myc antibodies (positioned above peak fractions). The elution
volumes of bovine serum albumin (BSA) and carbonic anhydrase (CA) are
indicated by arrows. The inset shows Western blot of lysates used for
purification, run on a denaturing gel, and developed using anti-Myc
antibodies. The apparent molecular size is noted.
|
|
Constitutive induction of urease genes by His mutants of UreR.
We did not observe urea inducibility using the chimeric fusion
proteins. We had reasoned earlier, however, that histidine residues
were likely involved in either urea binding or transmission of a
structural alteration induced by urea activation to the DNA-binding domain. Indeed, the active site of urease coordinates urea by interaction with four His, one Cys, one Asp, and one Lys residue (18). Thus, urea could be coordinated by similarly
configured His residues within UreR. Using site-directed mutagenesis,
eight His residues were changed to Ala. Six mutations (H5A, H73A,
H107A, H186A, H129A, and H152A) did not significantly alter urea
inducibility of the mutated UreR (data not shown). Two of
eight His-to-Ala mutants tested, however, H102A and H175A,
constitutively induced urease genes (i.e., in the absence of urea), as
assayed using the ureD-lacZ translational fusion to levels
that were not significantly different from the wild-type UreR level in
the presence of urea (Table 3). The
His102 residue resides in the N-terminal domain, the region predicted
to bind urea. Interestingly, the His175 residue resides in the linker
region that joins the dimerization domain and DNA-binding domain.
 |
DISCUSSION |
UreR chimeric proteins were constructed to identify and localize
functional domains of the AraC-like transcriptional activator of the
P. mirabilis urease gene cluster. Our studies led us to conclude that the N-terminal half of UreR contains the dimerization domain and the C-terminal half of UreR serves as the DNA-binding domain. Leucine residues in the putative dimerization domain of UreR,
conserved with respect to AraC and other UreR homologues, were required
to fully activate transcription. Site-directed mutagenesis studies were
consistent with their involvement in dimerization. While it is proposed
that urea binding by UreR is required for activation, construction of
the chimeric proteins did not allow us to elucidate this role. Two His
mutants of UreR, however, displayed constitutive induction of urease genes.
Our experimental results support the hypothesis that the dimerization
domain of UreR localizes to the N-terminal half of UreR. Repression of
psulA-lacZ by
UreR1-182-LexA1-87 is consistent with the
presence of a dimerization domain supplied by UreR.
LexA1-87 alone was unable to repress transcription from
psulA-lacZ (Fig. 5). Only when the N
terminus of UreR was fused to LexA1-87 was repression
evident, indicating the requirement for dimerization. Other studies
have demonstrated that the LexA1-87 as well as the
repressor requires a dimerization domain for full function (8,
10, 22). That dimerization occurs in the fusion protein is
further supported by the observation that
UreR1-182-LexA1-87 is capable of
retarding the mobility of a double-stranded oligonucleotide containing
the sulA promoter in a gel shift assay (Fig. 6).
LexA1-87-Myc-His, a stably expressed protein, does not
retard the mobility of the target DNA. Thus, the addition of a
dimerization domain, provided by the UreR N-terminal amino acid
sequences, to LexA1-87 is necessary and sufficient to
restore the DNA-binding capability of LexA1-87 for its
target, psulA.
A number of observations also led us to conclude that the
DNA-binding domain resides in the C-terminal half of UreR. We
demonstrated that a functional chimeric protein,
C/EBP302-350-UreR164-293, binds to a
double-stranded oligonucleotide containing the mapped UreR-binding site
(25) within pureD (Fig. 4). The
UreR-binding site, mapped by Thomas and Collins, is
57 to
34
upstream of the transcriptional start of ureD in the
P. mirabilis ureR-ureD intergenic region (25).
Interestingly,
C/EBP302-350-UreR164-293 activated
transcription from pureD to the same
degree in both the absence and presence of urea (Fig. 2). This finding is consistent with the hypothesis that the putative urea-binding site
resides in the nonhomologous N-terminal domain. The
C/EBP302-350-UreR164-293 fusion has
slightly less than optimal activation in comparison to UreR. This may
have resulted from constraints imparted on the UreR164-293 by the heterologous C/EBP dimerization
domain. The ability of the
C/EBP302-350-UreR164-293 to bind and
activate transcription from pureD is consistent
with DNA-binding specificity residing in the putative UreR DNA-binding domain. This assertion is further supported by the observation that in
the absence of a dimerizing mechanism, the UreR DNA-binding domain
alone was unable to activate transcription from
pureD-lacZ even though
UreR164-293 could recognize its target sequence (Fig.
2) when dimerized. Furthermore, these results suggest that a
dimerization domain, provided by C/EBP in this case, is necessary and
sufficient to allow the binding of the C-terminal portion of UreR to
the ureD promoter. Taken together, these results
suggest that, as in other AraC family members,
dimerization of UreR is required for activation of urease promoters and
that the DNA-binding domain, rather than the dimerization domain,
resides in the C-terminal portion of UreR.
UreR activates transcription from both
pureD and pureR in
a urea-inducible manner (6), leading to the hypothesis that UreR binds urea. Likely, this mechanism involves a
structural change induced by urea binding. We also hypothesized that
because the AraC family of transcriptional regulators contains little
or no homology in the N-terminal portion of the proteins, binding
specificity for an inducer molecule would likely reside in the
N-terminal portion of the protein (7). Although
UreR1-182-LexA1-87 represses
transcription from psulA-lacZ, the
hypothesized urea requirement for UreR function was not observed in the
-galactosidase assays (Fig. 5). The tertiary structure of the
UreR1-182-LexA1-87 fusion appears to
allow for UreR dimerization to occur but clearly eliminates the
urea-inducible mechanism. If UreR dimerizes via two different
conformations depending on whether urea is present or not, then
possibly only one of the dimerization conformations is attainable when
fused to LexA1-87, allowing for binding of the
UreR1-182-LexA1-87 fusion to
psulA-lacZ. This may account for the
unresponsiveness of UreR1-182-LexA1-87 to urea.
Nevertheless, some clues as to the mechanism of urea inducibility by
UreR were uncovered by site-directed mutagenesis. Interestingly, among
eight His-to-Ala mutants of UreR tested for urea inducibility, two
resulted in constitutive transcriptional activation from the ureD promoter in the absence of urea. His102 resides in the
putative urea-binding (N-terminal) domain. His175 resides in the amino acid sequence that comprises a linker region between the N-terminal and
C-terminal domains. It could be speculated that this latter residue
transmits the structural alteration that follows urea binding to the
C-terminal DNA-binding domain, resulting in binding to specific DNA
sequences within the ureR-ureD intergenic region.
AraC dimerizes via an antiparallel coiled-coil containing three
leucines that fits into a knobs-into-holes conformation at both ends of
the coil (23, 15). UreR retains these three conserved leucines in the same spatial orientation and relative location. PCR
site-directed mutagenesis of Leu147, Leu148, and Leu158 in UreR
demonstrates the requirement of these residues for transcriptional activation of pureD-lacZ (Fig. 7).
The levels of transcriptional activation for each of the single leucine
mutants of UreR are not significantly different from the wild-type UreR
level in the presence of urea. The double and triple leucine mutants,
however, show a dramatic decrease in activation in comparison to both
wild-type UreR and the single leucine mutants in both the presence and
absence of urea (as little as 6% of native UreR activity). These
results indicate that alteration of each one of the leucines alone is not sufficient to disrupt the protein structure to any degree in the
presence of urea. However, because both Leu147 and Leu148 from one
monomer may flank Leu158 from the other monomer and act as a
dimerization anchor at each end of the coiled-coil helix, the
mutation of both Leu147 and Leu148 would be expected to perturb the
native dimerization state. A mutation in one of the leucines still may
allow for the interaction between the nonmutated leucine and Leu158
from the other monomer. However, mutation of both Leu147 and Leu148 may
eliminate the pocket into which Leu158, from the other monomer, is
anchored. Surprisingly, while the native dimerization state may have
been altered, the triple Leu mutant remained a dimer. The purified
Myc-His derivative of the triple mutant eluted at the identical
fraction as purified UreR-Myc-His on a gel filtration column (Fig. 8),
indicating that under physiologic conditions the two monomers remained
associated. More drastic amino acid substitutions of the homologous
residues (Leu to Lys in combination with Leu to Ser) in a construct
expressing the N-terminal half of AraC did disrupt the dimeric state to
yield the monomers (15). Likely, this would be the case
for UreR as well. In this study, the Leu residues were conservatively
changed to only Ala. While this study is the first to show the
biological relevance of these critical leucine residues in UreR,
clearly additional studies are required to substantiate their precise role.
The UreR-Myc-His fusion was constructed to detect and follow a protein
that mimics wild-type UreR in vivo and in vitro. Although UreR-Myc-His
contains the c-Myc and His6 epitopes at the C terminus of UreR,
-galactosidase reporter activity demonstrated that
UreR-Myc-His activated transcription from
pureD-lacZ as well as wild-type UreR
(Fig. 2). Overexpression of UreR-Myc-His and detection by anti-Myc and
anti-His antibodies on a Western blot show that the fusion protein was
produced (Fig. 3). Furthermore, gel mobility shift assays demonstrated
that UreR-Myc-His was able to bind to pureD,
which resulted in a strong shift of labeled target DNA comparable to
the shift seen with wild-type UreR (data not shown).
Using protein fusion technology, we have provided evidence that the
AraC-like transcriptional activator UreR consists of dimerization and
DNA-binding domains. We have also elucidated a possible dimerization mechanism based on the knobs-into-holes conformation facilitated by
three leucine residues that are conserved within both UreR and AraC.
Our chimeric proteins were unresponsive to urea activation, and thus a
urea-binding domain could not be assigned although we identified two
key His residues that were involved in urea inducibility.
 |
ACKNOWLEDGMENTS |
This work was supported in part by National Institutes of Health
Public Health Service grant AI23328.
We thank Robert Schleif for the gifts of strains and plasmids. We thank
Magdeline Spence for skillful technical assistance. We thank Xin Li for
helpful discussions, technical advice, and critical review. We also
thank David Rasko, Susan Heimer, Janette Harro, and Angela Jansen for
critical review of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 655 W. Baltimore
St., BRB 13-009, Department of Microbiology and Immunology, Baltimore, MD 21201. Phone: (410) 706-0466. Fax: (410) 706-6751. E-mail: hmobley{at}umaryland.edu.
 |
REFERENCES |
| 1.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl (ed.).
1995.
Current protocols in molecular biology, p. 10.8.1-10.8.17.
John Wiley & Sons, Inc., New York, N.Y.
|
| 2.
|
Bustos, S. A., and R. F. Schleif.
1993.
Functional domains of the AraC protein.
Proc. Natl. Acad. Sci. USA
90:5638-5642[Abstract/Free Full Text].
|
| 3.
|
Coker, C.,
O. O. Bakare, and H. L. T. Mobley.
2000.
H-NS is a repressor of the Proteus mirabilis urease transcriptional activator gene ureR.
J. Bacteriol.
182:2649-2653[Abstract/Free Full Text].
|
| 4.
|
Collins, C. M., and S. E. F. D'Orazio.
1993.
Bacterial ureases: structure, regulation of expression and role in pathogenesis.
Mol. Microbiol.
9:907-913[Medline].
|
| 5.
|
D'Orazio, S. E. F., and C. M. Collins.
1993.
The plasmid-encoded urease gene cluster of the family Enterobacteriaceae is positively regulated by UreR, a member of the AraC family of transcriptional activators.
J. Bacteriol.
175:3459-3467[Abstract/Free Full Text].
|
| 6.
|
D'Orazio, S. E. F.,
V. Thomas, and C. M. Collins.
1996.
Activation of transcription at divergent urea-dependent promoters by the urease gene regulator UreR.
Mol. Microbiol.
21:643-655[CrossRef][Medline].
|
| 7.
|
Gallegos, M.,
R. Schleif,
A. Bairoch,
K. Hofmann, and J. L. Ramos.
1997.
AraC/XylS family of transcriptional regulators.
Microbiol. Mol. Biol. Rev.
61:393-410[Abstract].
|
| 8.
|
Granger-Schnarr, M.,
E. Benusiglio,
M. Schnarr, and P. Sassone-Corsi.
1992.
Transformation and transactivation suppressor activity of the c-Jun leucine zipper fused to a bacterial repressor.
Proc. Natl. Acad. Sci. USA
89:4236-4239[Abstract/Free Full Text].
|
| 9.
|
Ho, S. N.,
H. D. Hunt,
R. M. Horton,
J. K. Pullen, and L. R. Pease.
1989.
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
Gene
77:51-59[CrossRef][Medline].
|
| 10.
|
Hu, J. C.,
E. K. O'Shea,
P. S. Kim, and R. T. Sauer.
1990.
Sequence requirements for coiled-coils: analysis with lambda repressor-GCN4 leucine zipper fusions.
Science
250:1400-1403[Abstract/Free Full Text].
|
| 11.
|
Island, M. D., and H. L. T. Mobley.
1995.
Proteus mirabilis urease: operon fusion and linker insertion analysis of ure gene organization, regulation, and function.
J. Bacteriol.
177:5653-5660[Abstract/Free Full Text].
|
| 12.
|
Jones, B. D., and H. L. T. Mobley.
1989.
Proteus mirabilis urease: nucleotide sequence determination and comparison with jack bean urease.
J. Bacteriol.
171:6414-6422[Abstract/Free Full Text].
|
| 13.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
227:680-685[CrossRef][Medline].
|
| 14.
|
Lane, D.,
P. Prentki, and M. Chandler.
1992.
Use of gel retardation to analyze protein-nucleic acid interactions.
Microbiol. Rev.
56:509-528[Abstract/Free Full Text].
|
| 15.
|
LaRonde-LeBlanc, N., and C. Wolberger.
2000.
Characterization of the oligomeric states of wild type and mutant AraC.
Biochemistry
39:11593-11601[CrossRef][Medline].
|
| 16.
|
Mobley, H. L. T., and J. W. Warren.
1987.
Urease-positive bacteriuria and obstruction of long-term urinary catheters.
J. Clin. Microbiol.
25:2216-2217[Abstract/Free Full Text].
|
| 17.
|
Mobley, H. L. T., and R. Belas.
1995.
Swarming and pathogenicity of Proteus mirabilis in the urinary tract.
Trends Microbiol.
3:280-284[CrossRef][Medline].
|
| 18.
|
Mobley, H. L. T.,
M. D. Island, and R. P. Hausinger.
1995.
Molecular biology of microbial ureases.
Microbiol. Rev.
59:451-480[Abstract/Free Full Text].
|
| 19.
|
Nicholson, E. B.,
E. A. Concaugh,
P. A. Foxall,
M. D. Island, and H. L. T. Mobley.
1993.
Proteus mirabilis urease: transcriptional regulation by UreR.
J. Bacteriol.
175:465-473[Abstract/Free Full Text].
|
| 20.
|
Platt, T.,
B. Meuler-Hill, and J. Miller.
1972.
Assays of -galactosidase activity, p. 352-355.
In
J. Miller (ed.), Experiments in molecular genetics. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 21.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 22.
|
Schmidt-Dörr, T.,
P. Oertel-Buchheit,
C. Pernelle,
L. Bracco,
M. Schnarr, and M. Granger-Schnarr.
1991.
Construction, purification, and characterization of a hybrid protein comprising DNA binding domain of the LexA repressor and the Jun leucine zipper: a circular dichroism and mutagenesis study.
Biochemistry
30:9657-9664[CrossRef][Medline].
|
| 23.
|
Soisson, S. M.,
B. MacDougall-Shackleton,
R. Schleif, and C. Wolberger.
1997.
Structural basis for ligand-regulated oligomerization of AraC.
Science
276:421-425[Abstract/Free Full Text].
|
| 24.
|
Sriwanthana, B.,
M. D. Island, and H. L. T. Mobley.
1993.
Sequence of the Proteus mirabilis urease accessory gene ureG.
Gene
129:103-106[CrossRef][Medline].
|
| 25.
|
Thomas, V., and C. M. Collins.
1999.
Identification of UreR binding sites in the Enterobacteriaceae plasmid-encoded and Proteus mirabilis urease gene operons.
Mol. Microbiol.
31:1417-1428[CrossRef][Medline].
|
Journal of Bacteriology, August 2001, p. 4526-4535, Vol. 183, No. 15
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.15.4526-4535.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dominguez-Cuevas, P., Marin, P., Busby, S., Ramos, J. L., Marques, S.
(2008). Roles of Effectors in XylS-Dependent Transcription Activation: Intramolecular Domain Derepression and DNA Binding. J. Bacteriol.
190: 3118-3128
[Abstract]
[Full Text]
-
Basturea, G. N., Bodero, M. D., Moreno, M. E., Munson, G. P.
(2008). Residues near the Amino Terminus of Rns Are Essential for Positive Autoregulation and DNA Binding. J. Bacteriol.
190: 2279-2285
[Abstract]
[Full Text]
-
Wickstrum, J. R., Skredenske, J. M., Kolin, A., Jin, D. J., Fang, J., Egan, S. M.
(2007). Transcription Activation by the DNA-Binding Domain of the AraC Family Protein RhaS in the Absence of Its Effector-Binding Domain. J. Bacteriol.
189: 4984-4993
[Abstract]
[Full Text]
-
Wickstrum, J. R., Egan, S. M.
(2004). Amino Acid Contacts between Sigma 70 Domain 4 and the Transcription Activators RhaS and RhaR. J. Bacteriol.
186: 6277-6285
[Abstract]
[Full Text]
-
Poore, C. A., Mobley, H. L. T.
(2003). Differential regulation of the Proteus mirabilis urease gene cluster by UreR and H-NS. Microbiology
149: 3383-3394
[Abstract]
[Full Text]
-
Ruiz, R., Marques, S., Ramos, J. L.
(2003). Leucines 193 and 194 at the N-Terminal Domain of the XylS Protein, the Positive Transcriptional Regulator of the TOL meta-Cleavage Pathway, Are Involved in Dimerization. J. Bacteriol.
185: 3036-3041
[Abstract]
[Full Text]
-
Ibarra, J. A., Villalba, M. I., Puente, J. L.
(2003). Identification of the DNA Binding Sites of PerA, the Transcriptional Activator of the bfp and per Operons in Enteropathogenic Escherichia coli. J. Bacteriol.
185: 2835-2847
[Abstract]
[Full Text]
-
Dattelbaum, J. D., Lockatell, C. V., Johnson, D. E., Mobley, H. L. T.
(2003). UreR, the Transcriptional Activator of the Proteus mirabilis Urease Gene Cluster, Is Required for Urease Activity and Virulence in Experimental Urinary Tract Infections. Infect. Immun.
71: 1026-1030
[Abstract]
[Full Text]
-
Gendlina, I., Gutman, D. M., Thomas, V., Collins, C. M.
(2002). Urea-dependent Signal Transduction by the Virulence Regulator UreR. J. Biol. Chem.
277: 37349-37358
[Abstract]
[Full Text]
![]()